{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T18:11:18Z","timestamp":1774375878514,"version":"3.50.1"},"reference-count":28,"publisher":"The Pediatric Pharmacy Association","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:p>Maternal antidepressant use has increased during the past 2 decades, with venlafaxine emerging as a common agent during pregnancy. Both venlafaxine and its active metabolite possess prolonged half-lives in adults; however, abrupt discontinuation may lead to withdrawal including irritability, jitteriness, lethargy, restlessness, and insomnia. The drug and its metabolite readily cross the placenta, posing additional considerations during pregnancy. Two neonates were admitted to our hospital on 5 and 6 days of life with hypothermia and lethargy among other symptoms of neonatal abstinence syndrome (NAS) requiring an extensive medical workup. Both neonates were exposed to venlafaxine in utero and exclusively fed infant formula since birth. Given that venlafaxine crosses the placenta and into breastmilk, NAS was suspected as a result of the abrupt discontinuation of venlafaxine upon delivery, and the decision was made to introduce mothers\u2019 breast milk. Symptoms of NAS, including hypothermia, resolved in both patients. The reported incidence of NAS with venlafaxine alone is limited, likely due to variation in breastfeeding practices among new mothers. Diagnosis of NAS due to venlafaxine requires a high index of suspicion because symptoms are nonspecific and the presentation may be delayed after birth. The effective treatment of NAS using mothers\u2019 breast milk illustrates the importance of counseling mothers to provide breast milk as a preventative strategy for withdrawal in their newborns. The cases involving the 2 neonates described in this article emphasize the importance of assessing in utero exposure to medications beyond the immediate newborn period and their possible role in causing unusual symptoms in newborns.<\/jats:p>","DOI":"10.5863\/1551-6776-29.6.654","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T21:37:09Z","timestamp":1733780229000},"page":"654-659","source":"Crossref","is-referenced-by-count":2,"title":["Hypothermia as a Presenting Sign of Venlafaxine-Induced Neonatal Abstinence Syndrome in 2 Neonates"],"prefix":"10.5863","volume":"29","author":[{"given":"Matthew","family":"Oswald","sequence":"first","affiliation":[{"name":"Department of Pharmacy (MO, GE-C), NYU Langone - Long Island, Department of Pediatrics (MC), NYU Langone - Long Island, Mineola, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gladys","family":"El-Chaar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (MO, GE-C), NYU Langone - Long Island, Department of Pediatrics (MC), NYU Langone - Long Island, Mineola, NY"},{"name":"Department of Clinical Health Professions (GE-C), St. John\u2019s University College of Pharmacy and Health Sciences, Queens, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marguerite","family":"Canter","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (MO, GE-C), NYU Langone - Long Island, Department of Pediatrics (MC), NYU Langone - Long Island, Mineola, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"issue":"5 pt 1","key":"2024121714204877700_i2331-348X-29-6-654-b01","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/01.AOG.0000183597.31630.db","article-title":"Perinatal depression: a systematic review of prevalence and incidence","volume":"106","author":"Gavin","year":"2005","journal-title":"Obstet Gynecol"},{"issue":"1","key":"2024121714204877700_i2331-348X-29-6-654-b02","doi-asserted-by":"crossref","first-page":"51.e1","DOI":"10.1016\/j.ajog.2011.02.029","article-title":"Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008","volume":"205","author":"Mitchell","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"2024121714204877700_i2331-348X-29-6-654-b03","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hup.2473","article-title":"The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review","volume":"30","author":"Bellantuono","year":"2015","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"2024121714204877700_i2331-348X-29-6-654-b04","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archpedi.160.2.173","article-title":"Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants","volume":"160","author":"Levinson-Castiel","year":"2006","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"10","key":"2024121714204877700_i2331-348X-29-6-654-b05","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s40264-016-0435-8","article-title":"Neonatal adaptation issues after maternal exposure to prescription drugs: withdrawal syndromes and residual pharmacological effects","volume":"39","author":"Convertino","year":"2016","journal-title":"Drug Saf"},{"issue":"2","key":"2024121714204877700_i2331-348X-29-6-654-b06","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/070674370304800207","article-title":"A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy","volume":"48","author":"Einarson","year":"2003","journal-title":"Can J Psychiatry"},{"issue":"4","key":"2024121714204877700_i2331-348X-29-6-654-b07","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/070674370905400405","article-title":"Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study","volume":"54","author":"Einarson","year":"2009","journal-title":"Can J Psychiatry"},{"key":"2024121714204877700_i2331-348X-29-6-654-b08","volume-title":"StatPearls","author":"Singh","year":"2022"},{"key":"2024121714204877700_i2331-348X-29-6-654-b09","unstructured":"Effexor (venlafaxine hydrochloride) [package insert]. Wyeth Pharmaceuticals. US Food and Drug Administration website. Published 2006. Accessed September 17 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/020151s044,020699s071lbl.pdf"},{"issue":"7","key":"2024121714204877700_i2331-348X-29-6-654-b10","doi-asserted-by":"crossref","first-page":"772","DOI":"10.2174\/0929867324666170712165042","article-title":"New-generation, non-SSRI antidepressants: therapeutic drug monitoring and pharmacological interactions\u2014Part 1: SNRIs, SMSs, SARIs","volume":"25","author":"Mandrioli","year":"2018","journal-title":"Curr Med Chem"},{"issue":"2","key":"2024121714204877700_i2331-348X-29-6-654-b11","first-page":"222","article-title":"Neonatal abstinence syndrome: a call for mother-infant dyad treatment approach","volume":"104","author":"Mossabeb","year":"2021","journal-title":"Am Fam Physician"},{"issue":"19","key":"2024121714204877700_i2331-348X-29-6-654-b12","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1001\/jama.293.19.2372","article-title":"Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications","volume":"293","author":"Moses-Kolko","year":"2005","journal-title":"JAMA"},{"issue":"7","key":"2024121714204877700_i2331-348X-29-6-654-b13","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1001\/archpsyc.60.7.720","article-title":"Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations","volume":"60","author":"Laine","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"2024121714204877700_i2331-348X-29-6-654-b14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/FTD.0b013e3181a58fb4","article-title":"Maternal use of venlafaxine near term: correlation between neonatal effects and plasma concentrations","volume":"31","author":"Boucher","year":"2009","journal-title":"Ther Drug Monit"},{"issue":"1","key":"2024121714204877700_i2331-348X-29-6-654-b15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1542\/peds.2006-2133","article-title":"Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates","volume":"119","author":"Ferreira","year":"2007","journal-title":"Pediatrics"},{"issue":"1","key":"2024121714204877700_i2331-348X-29-6-654-b16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5005\/jp-journals-10009-1345","article-title":"Psychotropic medication use during pregnancy and lactation: role of ultrasound assessment","volume":"8","author":"Matthys","year":"2014","journal-title":"Donald Sch J Ultrasound Obstet Gynecol"},{"key":"2024121714204877700_i2331-348X-29-6-654-b17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/acps.12479","article-title":"Use of psychotropic drugs during pregnancy and breast-feeding","volume":"445","author":"Larsen","year":"2015","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"2","key":"2024121714204877700_i2331-348X-29-6-654-b18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejpn.2016.11.003","article-title":"Neonatal venlafaxine discontinuation syndrome: a mini-review","volume":"21","author":"Holland","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"2024121714204877700_i2331-348X-29-6-654-b19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.0306-5251.2001.01518.x","article-title":"Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants","volume":"53","author":"Ilett","year":"2002","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"2024121714204877700_i2331-348X-29-6-654-b20","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1124\/dmd.108.021873","article-title":"Developmental changes in human liver CYP2D6 expression","volume":"36","author":"Stevens","year":"2008","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"7","key":"2024121714204877700_i2331-348X-29-6-654-b21","doi-asserted-by":"crossref","first-page":"994","DOI":"10.4088\/JCP.10m06461","article-title":"Mother-infant antidepressant concentrations, maternal depression, and perinatal events","volume":"72","author":"Sit","year":"2011","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"2024121714204877700_i2331-348X-29-6-654-b22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1017\/S1461145704004286","article-title":"A pilot study of newer antidepressant concentrations in cord and maternal serum and possible effects in the neonate","volume":"7","author":"Rampono","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"issue":"10","key":"2024121714204877700_i2331-348X-29-6-654-b23","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S0006-3223(00)00958-6","article-title":"Amniotic fluid and umbilical cord blood concentrations of antidepressants in three women","volume":"48","author":"Hostetter","year":"2000","journal-title":"Biol Psychiatry"},{"issue":"9","key":"2024121714204877700_i2331-348X-29-6-654-b24","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.4088\/JCP.08m05001","article-title":"Venlafaxine in human breast milk and nursing infant plasma: determination of exposure","volume":"70","author":"Newport","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"2024121714204877700_i2331-348X-29-6-654-b25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1701-2163(16)32135-1","article-title":"Can venlafaxine in breast milk attenuate the norepinephrine and serotonin reuptake neonatal withdrawal syndrome","volume":"28","author":"Koren","year":"2006","journal-title":"J Obstet Gynaecol Can"},{"issue":"12","key":"2024121714204877700_i2331-348X-29-6-654-b26","doi-asserted-by":"crossref","first-page":"2089-a","DOI":"10.1176\/appi.ajp.158.12.2089-a","article-title":"Venlafaxine and breast-feeding","volume":"158","author":"Hendrick","year":"2001","journal-title":"Am J Psychiatry"},{"key":"2024121714204877700_i2331-348X-29-6-654-b27","volume-title":"Briggs Drugs in Pregnancy and Lactation\u202f: A Reference Guide to Fetal and Neonatal Risk","author":"Briggs","year":"2017","edition":"12th ed."},{"issue":"28","key":"2024121714204877700_i2331-348X-29-6-654-b28","first-page":"1370","article-title":"Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy [in Dutch]","volume":"147","author":"de Moor","year":"2003","journal-title":"Ned Tijdschr Geneeskd"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/6\/654\/3465933\/i2331-348x-29-6-654.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/6\/654\/3465933\/i2331-348x-29-6-654.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:42:08Z","timestamp":1738780928000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/29\/6\/article-p654.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12,9]]},"published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-29.6.654","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}